oral tirzepatide eli lilly orforglipron GLP-1 phase 3 weight loss trial tirzepatide pdufa date Eli Lilly's

Research has shown a potential link between the use of GLP-1 medications and an increased risk of gallbladder issues, primarily: Why might GLP-1s be linked to these issues

There is evidence that they can help with a range of chronic diseases, including cardiovascular and kidney disease

These systems allow for more versatile activation mechanisms Fig

Identifying genetic predispositions to rapid weight loss or orthostatic changes lets PlexusDx clinicians preempt vertigo through targeted hydration, electrolyte, and dosing adjustments personalized to your biology

"Mary Shorb Lecture in Nutrition"

Microdosing allows fine-tuning based on how your body responds